危重患儿胃残余量评估:GASTRIC-PICU随机临床试验
该实用型多中心随机非劣效性试验纳入英国23个和瑞士1个儿童重症监护病房的4700例0至16岁接受有创通气并开始肠内喂养的患儿,1:1随机分为不常规评估胃残余量组(仅依据临床征象判断喂养耐受性)与常规每6小时评估胃残余量组。主要临床复合终点为30天生存与无机械通气天数,不常规评估组不劣于常规评估组(两组中位数均为25天,校正OR 0.95,95%CI 0.86-1.05)。主要营养终点为72小时能量需求达标百分比,不常规评估组为80.3%,常规评估组为76.8%(校正均差3.2个百分点,95%CI 1.3-5.2,P<.001)。
要点
- 在4700例随机、4460例意向性分析人群中,不常规评估胃残余量组30天生存与无机械通气天数不劣于每6小时评估组(两组中位数均为25天,校正OR 0.95,95%CI 0.86-1.05)。
- 不常规评估胃残余量组72小时能量需求达标百分比为80.3%,常规每6小时评估组为76.8%,校正均差3.2个百分点(95%CI 1.3-5.2,P<.001)。
- 符合方案分析结果与意向性分析一致(校正OR 1.01,95%CI 0.90-1.13)。
- 不常规评估组仅依据临床征象判断喂养耐受性,其余肠内喂养实践均遵循当地方案。
适用人群与场景
- 英国23个儿童重症监护病房和瑞士1个儿童重症监护病房中0至16岁接受有创通气并开始肠内喂养的危重患儿。
处置流程与药物剂量
- 不常规评估胃残余量组:不常规评估胃残余量,仅依据临床征象判断喂养耐受性。
- 常规评估组:每6小时评估一次胃残余量以指导肠内喂养。
- 两组其余肠内喂养实践均遵循当地方案。
研究设计与关键结果
- 实用型、多中心、随机、非劣效性试验,纳入英国23个和瑞士1个儿童重症监护病房的4700例患儿(不常规评估组2352例,常规评估组2348例),4460例纳入意向性分析(中位年龄8个月,IQR 1-44个月;女性1925例,42.6%)。
- 主要临床复合终点(30天生存与无机械通气天数):不常规评估组中位数25天(IQR 21-27),常规评估组中位数25天(IQR 21-27),校正OR 0.95(95%CI 0.86-1.05),不常规评估不劣于每6小时评估。
- 符合方案分析:校正OR 1.01(95%CI 0.90-1.13),与意向性分析一致。
- 主要营养终点(72小时能量需求达标百分比):不常规评估组80.3%,常规评估组76.8%,校正均差3.2个百分点(95%CI 1.3-5.2,P<.001)。
证据类型、等级与局限
- 证据类型:实用型、多中心、随机、非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在接受肠内喂养的危重患儿中,不常规评估胃残余量不劣于每6小时评估一次,且显著提高72小时营养达标率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Routine assessment of gastric residual volume (GRV) to guide enteral feeding in critically ill children is widespread but not based on evidence. Perceived high gastric volumes often lead to withholding feeds, impairing nutritional delivery.
OBJECTIVE: To evaluate the effect of not routinely assessing GRV compared with assessments at least every 6 hours in children undergoing mechanical ventilation on the duration of mechanical ventilation and survival and achievement of nutritional targets.
DESIGN, SETTING, AND PARTICIPANTS: A pragmatic, multicenter, randomized, noninferiority trial in 23 pediatric intensive care units (PICUs) in the UK and 1 in Switzerland. A total of 4700 children aged 0 to 16 years who were receiving invasive ventilation and starting enteral feeds were recruited between June 29, 2023, and December 7, 2025, with 30-day follow-up completed on January 6, 2026.
INTERVENTIONS: Children were randomized (1:1) to receive usual care (GRV assessment every 6 hours) or no routine GRV assessment to guide enteral feeding. In the no routine GRV assessment group, feed tolerance was assessed using only clinical signs. All other enteral feeding practices followed local protocols.
MAIN OUTCOMES AND MEASURES: The clinical co-primary outcome (noninferiority) was a composite of survival and days free from mechanical ventilation at 30 days. The nutritional co-primary outcome (superiority) was the percentage of children meeting energy requirements by 72 hours.
RESULTS: Of the 4700 children randomized (2352 to the no routine GRV assessment group and 2348 to the usual care group), 4460 were included in the intention-to-treat analysis (median [IQR] age, 8 [1-44] months; 1925 [42.6%] females). No routine GRV assessment was noninferior to regular 6-hourly assessments for survival and days free from mechanical ventilation at 30 days (median [IQR], 25 [21-27] days in both groups; adjusted odds ratio [OR], 0.95 [95% CI, 0.86-1.05]). Results of the per-protocol analysis were consistent with the intention-to-treat analysis (adjusted OR, 1.01 [95% CI, 0.90-1.13]). The mean percentage of energy requirements achieved by 72 hours was 80.3% in the no routine GRV assessment group and 76.8% in the usual care group (adjusted mean difference, 3.2 [95% CI, 1.3-5.2] percentage points; P < .001).
CONCLUSIONS AND RELEVANCE: Among critically ill children being enterally fed, not assessing GRV routinely was noninferior to regular assessments every 6 hours and significantly increased nutritional achievement at 72 hours.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN79668198.
参考来源
- Tume LN, Mouncey PR, Broomhall JM, et al. Gastric Residual Volume Assessment in Critically Ill Children: The GASTRIC-PICU Randomized Clinical Trial. JAMA. 2026. PMID: 42283228. doi:10.1001/jama.2026.10639
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。